The clinical consequences of ANXA1 loss are supported by earlier findings, showing that depletion of ANXA1 was also detected in cerebrovascular capillaries and serum of MS and AD patients and respective experimental models in which a disrupted BBB is a major requirement for the onset of disease [20,48]. This evidence concerns the gene ANXA1 and Alzheimer disease.